OmniaBio is a Hamilton-based contract development and manufacturing organization focused on cell and gene therapy. The company’s website emphasizes process development, analytical development, GMP manufacturing, autologous manufacturing, cell banking, regulatory guidance, and commercial-scale production. Its platform expertise specifically references immune cell therapies, lentiviral vector workflows, and iPSC-based programs supported by advanced automation and AI-enabled manufacturing.